From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Last Updated: Thursday, April 10, 2025

Researchers analyzing the frequency of recurring gene mutations and connection with biomarkers in patients with relapsed/refractory DLBCL found that biomarker profiles differed between younger and elderly patients, with a higher frequency of BCL2 translocations in younger patients, and higher numbers of ABC subtypes and MYC protein expression in the elderly. They also noted that mutations in CREBBP and TNFRSF14 were associated with shorter overall survival only in younger patients, and a higher proportion of GNA13 mutations was detected in female patients of the elderly DLBCL patient cohort.

HemaSphere
Advertisement
News & Literature Highlights

2025 American Society of Clinical Oncology Annual Meeting Abstract

Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study.

2025 American Society of Clinical Oncology Annual Meeting Abstract

Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.

2025 American Society of Clinical Oncology Annual Meeting Abstract

Impact of CAR T cell therapy product in the clinical outcome of patients with relapsed/refractory diffuse large B-cell lymphoma.

2025 Transplantation & Cellular Therapy Meetings Abstract

Tandem CD20-CD19-directed non-cryopreserved CAR T cells - zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma - interim results from a phase 2 pivotal study (DALY II USA)

Nature Cancer

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

HemaSphere

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Journal of Clinical Oncology

Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma

OncLive

ctDNA testing joins NCCN Guidelines for MRD assessment in DLBCL

The Lancet

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

Advertisement
Advertisement